# SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

> **NCT04079166** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Scancell Ltd** · enrollment: 173 (estimated)

## Conditions studied

- Malignant Melanoma
- Melanoma (Skin)
- Melanoma Stage III
- Melanoma Stage IV

## Interventions

- **BIOLOGICAL:** SCIB1 or iSCIB1+ DNA vaccine

## Key facts

- **NCT ID:** NCT04079166
- **Lead sponsor:** Scancell Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-19
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 173 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04079166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04079166, "SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT04079166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*